Combination of transcatheter arterial embolization and percutaneous ethanol injection for hepatocellular carcinoma: comparison of efficacies of doxorubicin and epirubicin in transcatheter arterial embolization.
We administered a combination of transcatheter arterial embolization (TAE) and percutaneous ethanol injection (PEI) (ie, pretreatment with TAE and subsequent PEI) to treat 56 patients with multiple lesions (number of nodules < or = 3) or a single large (diameter > or = 3 cm) encapsulated lesion of hepatocellular carcinoma. The TAE included doxorubicin (40 mg) in 32 cases and epirubicin (mean, 82 mg) in the remaining 24 cases, and the efficacies of the two were compared. The therapeutic efficacy was evaluated on the basis of the survival rate and recurrence-free survival rate revealed by clinical follow-up. Both rates showed significant differences between the doxorubicin and epirubicin groups, with both being superior in the epirubicin group. It was surmised that epirubicin is a useful chemotherapeutic agent in TAE for patients with hepatocellular carcinoma.
Nakamura
S
S
Third Department of Internal Medicine, Yokohama City University School of Medicine, Kanazawa-ku, Japan.
Tanaka
K
K
D000368:Aged; D000369:Aged, 80 and over; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage* / Q000009:adverse effects; D006528:Carcinoma, Hepatocellular / Q000401:mortality / Q000628:therapy*; D016461:Chemoembolization, Therapeutic; D003131:Combined Modality Therapy; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D015251:Epirubicin / Q000008:administration & dosage* / Q000009:adverse effects; D000431:Ethanol / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D006801:Humans; D015552:Injections, Intralesional; D008113:Liver Neoplasms / Q000401:mortality / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D015996:Survival Rate
D000903:Antibiotics, Antineoplastic; D000431:Ethanol; D015251:Epirubicin; D004317:Doxorubicin